Pharma

Your Article Summary

See Latest Articles

European Commission Grants Conditional Marketing Authorization to Cayston for the Treatment of Chronic Pulmonary Infections Due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis
Gilead, 09/24/09

Gilead Sciences, Inc. announced that the European Commission has granted conditional marketing authorization for Cayston(R) 75 mg powder and solvent for nebuliser solution for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis aged 18 years and older. Cayston will be made available in certain countries of the European Union, subject to the requirements of national authorities, beginning in early 2010.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/25/09

Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09

AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09

 See all of Drug/Product Approvals

Today in Marketing/Media/ROI...keeping you current

Receive free subspecialty "5-minute updates" via email

Chugai Revises Corporate Advertisement for First Time in Four Years
Chugai Pharmaceutical Co., 11/25/09

Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09

Medtronic Introduces 3D Recon Service to Enhance Endovascular Treatment of Aortic Aneurysms
Medtronic, 11/20/09

 See all of Marketing/Media/ROI